|
A new class of agents known as c-Src inhibitors is being tested ina number of different ways to treat breast cancer , but researchers at Georgetown Lombardi Comprehensive CancerCenter caution that they should not be used in combination withestrogen to treat endocrine resistant breast cancer. That's because their new study, reported at the AmericanAssociation for Cancer Research (AACR) Annual Meeting 2012, showsthat using estrogen and a c-Src inhibitor, PP2, cancel each otherout. The benefit once seen in using estrogen was gone once PP2, aninhibitor of the Src-family of kinases used for laboratory studies,was added. Instead, the findings suggest that using a c-Src inhibitor alonemay offer another treatment option to estrogen-receptor-positivebreast cancer patients whose tumor no longer responds to tamoxifenor aromatase inhibitors, explains the study's lead researcher, PingFan, Ph.D. Her research is conducted in the lab of V. Craig Jordan,OBE, PhD, DSc, FMedSci, scientific director at Georgetown Lombardi. Most c-Src inhibitors have been approved for use in blood cancers and some are now being tested in solid cancers including breastcancer. C-Src helps control signaling pathways associated withgrowth, survival and cell migration, and increased activity of thisprotein has been observed in multiple tumor types. The study results came about because a Georgetown Lombardi researchteam, led by Jordan, was testing whether a combination of estrogenand PP2, an inhibitor of c-Src used in laboratory experiments,could work synergistically to destroy breast cancer cells that nolonger responded to endocrine therapy. Clinical studies have shown that, for reasons that have not beenfully explained yet, about 30 percent of endocrine resistant breasttumors respond to low doses of estrogen. The Georgetown Lombardistudy was designed to see if using PP2 with estrogen could producea stronger therapeutic outcome. What they found was unexpected - there was less, not more, of akilling effect when the two drugs were used together in the lab.Further investigation concluded that c-Src, one of the family ofSrc kinases inhibited by PP2, "is one of the important molecules inestrogen-stimulated pathways, so using an inhibitor of c-Srceliminates the beneficial effect of estrogen," says Fan. They also found evidence that estrogen induces expression ofmultiple genes that act en masse to kill breast cancer cells. "Our data suggest these two drugs should not be used together inresistant cancers," Fan says. Additional References Citations. I am an expert from projectorlamp-bulb.com, while we provides the quality product, such as SONY Projector Lamp Manufacturer , MITSUBISHI Projector Lamp Manufacturer, Projector Lamp Bulb,and more.
Related Articles -
SONY Projector Lamp Manufacturer, MITSUBISHI Projector Lamp Manufacturer,
|
